Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
A phase 2 trial of Artesunate vaginal insert in vaginal cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.
Overview
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) is a phase 2 interventional study registered as NCT04098744 by Frantz Viral Therapeutics, LLC, with 78 participants planned, started 2020-09-09 and due to reach its primary completion in 2026-07-31. Interventions recorded: Artesunate vaginal insert and Placebo vaginal insert.
Setting
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)
Phase
Phase 2
Sponsor
Frantz Viral Therapeutics, LLC
Registry
Enrolled
78
Similar pages
not linked directly; found by shared links- TrialPhase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
Shares Vaginal cancer and the tag pipeline.
- TrialImmunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shares Vaginal cancer and the tag pipeline.